Bausch Health Companies Stock News

LAVAL, Quebec, Feb. 23, 2022 /PRNewswire/ -- Fourth-Quarter 2021 Financial Results Revenues of $2.196 Billion GAAP Net Income of $69 Million Adjusted EBITDA (non-GAAP)1 of $909 Million GAAP Cash Generated from Operations of $24 Million Full-Year 2021 Financial Results Revenues of $8.434

Shares of Bausch Health Companies Inc. BHC, -1.34% rallied 2.3% in premarket trading Wednesday, after the health care products company swung to fourth-quarter net income, while revenue and the full-ye

Let us take a look at five drug/biotech companies, namely, BMRN, CLVS, TBPH, BHC and GBT, which are due to release their quarterly results on Feb 23.

Bausch Health Companies (NYSE:BHC) is scheduled to announce Q4 earnings results on Wednesday, February 23rd, before market open.The consensus EPS Estimate is $1.15 vs

Let us take a look at five drug/biotech companies, namely, BMRN, CLVS, TBPH, BHC and GBT, which are due to release their quarterly results on Feb 23.

An update on the IPO of Bausch+Lomb and regular top-line and bottom-line numbers will grab investors' attention when BHC reports Q4 results.

An update on the IPO of Bausch+Lomb and regular top-line and bottom-line numbers will grab investors' attention when BHC reports Q4 results.

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front, the Food and Drug A

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front, the Food and Drug Administration approved Agios Pharmaceuticals, Inc.''s (NASDAQ: AGIO ) mitapivat for treating pyruvate kinase deficiency, a rare, inherited metabolic disorder. Avenue Therapeutics, Inc. (NASDAQ: ATXI ) stock tumbled close to 60% after an FDA panel found that data included in the company''s new drug application for pain drug tramadol was inadequate to support approval. GlaxoSmithKline plc (NYSE: GSK ) and Sanofi (NASDAQ: SNY )- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) suffered setbacks after their respective late-stage studies of respiratory syncytial vaccine candidate in pregnant women and Dupixent as a treatment option for skin rash had to be halted. Here are the key catalysts for the unfolding week: Conferences 49th Annual Scientific and Technology Meeting of the American Auditory Society, AAS (hybrid event) Feb. 24-27, in Scottsdale, Arizona & online Multidisciplinary Head and Neck Cancers Symposium (virtual event): Feb. 24-27, in Phoenix, Arizona & online International Society of Nephrology''s World Congress of Nephrology, or WCN, 2022 (hybrid event): Feb. 24-27, in Kuala Lumpur & online PDUFA Dates The FDA has set a PDUFA date of Friday, Feb. 25, for its new drug application for Reata Pharmaceuticals, Inc.''s (NASDAQ: RETA ) Bardoxolone.

Federal prosecutors are reportedly ramping up a probe into the activities of short sellers, serving subpoenas and seizing hard drives and mobile phones of prominent "activist" short sellers. What Happ

Solta Medical has filed for a U.S. IPO as part of a separation process from its parent firm, Bausch Health Companies. The firm designs and sells medical aesthetic devices in 50 countries worldwide.

Someone with a lot of money to spend has taken a bearish stance on Bausch Health Companies (NYSE: BHC ). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don''t know. But when something this big happens with BHC, it often means somebody knows something is about to happen. Today, Benzinga ''s options scanner spotted 19 options trades for Bausch Health Companies . This isn''t normal. The overall sentiment of these big-money traders is split between 36% bullish and 63%, bearish. Out of all of the options we uncovered, there was 1 put, for a total … Full story available on Benzinga.com

As Club members know, we''re looking to these IPOs as a means of unlocking value by separating the three core operating business.

Solta Medical, a wholly owned subsidiary of Bausch Health Companies (BHC), has filed to hold an initial public offering. Solta is a maker of medical devices for aesthetic skin treatments.